Effects of a New Enzymatic Debrider (SN514-066b) on Eschar Protein Digestion, Burn Wound Debridement, and Healthy Skin Irritation
Advances in Wound Care · 2025
DOI: 10.1089/wound.2024.0215 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advances in Wound Care, 2025. Verfasst von Herbert B Slade und 6 weiteren Autor:innen. Beteiligte Einrichtung: SERDA bv, Amsterdam, the Netherlands. Hauptthemen laut MEDLINE: Debridement, Burns. Die Arbeit nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objective
SN514 is a thermolysin-like enzyme under development as a debrider. Preclinical and non-clinical studies supported a first in human healthy volunteer study to predict the need for protection of periwound skin. Approach: Pharmacologic activity testing compared in vitro digestion of collagen, fibrin, and elastin with relevant enzymes. A Yorkshire pig model of burn injury was used to evaluate debridement over 10 days and effects on intact skin. A human 21-day cumulative irritation study using Webril patches taped to the backs of 38 healthy adult volunteers compared four enzyme concentrations (0.10%, 0.20%, 0.40%, and 0.80% w/w) with the hydrogel vehicle, saline (low irritant control), and 0.2% sodium lauryl sulfate (positive irritant control) using randomized placements and blinded evaluation.
Results
SN514 showed excellent digestion of fibrin, elastin, and collagen in vitro . Burn wound studies in Yorkshire pigs showed efficient eschar debridement with minimal periwound erythema. Direct treatment on intact porcine skin for 5 days produced no to limited erythema. The preclinical findings of minimal irritation with SN514 were verified by a Phase 1 first-in-human 21-day cumulative skin irritation test. Irritation was observed to increase stepwise by concentration, confirming formulation accuracy. Each enzyme concentration was found to be “possibly mild in use” (Berger and Bowman method). No treatment emergent adverse events were observed during the study. Innovation: A fast-acting enzyme with a favorable irritation profile, prepared as a stable, ready to use hydrogel formulation, overcomes many recognized shortcomings of enzyme debriders.
Conclusion
The overall findings support clinical dose range testing for tolerance and preliminary efficacy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- SERDA bv, Amsterdam, the Netherlands.
- ALS Global, Irving, Texas, USA.
- McCoy Clinical Consulting LLC, Grapevine, Texas, USA.
- Macro Biologics, Fort Worth, Texas, USA.
- Smith & Nephew plc, Fort Worth, Texas, USA.
- Suzhou MicroPort Regenerative Medicine Technology Co., Ltd, Shanghai, China.
ORCID-Profile: Herbert B Slade
Zitieren
APA
Slade, H. B., Reece, B. T., McCoy, N. D., Roche, E. D., Jovanovic, A. V., Shi, L., & Jacobson, N. (2025). Effects of a New Enzymatic Debrider (SN514-066b) on Eschar Protein Digestion, Burn Wound Debridement, and Healthy Skin Irritation. Advances in Wound Care. https://doi.org/10.1089/wound.2024.0215
Vancouver
Slade HB, Reece BT, McCoy ND, Roche ED, Jovanovic AV, Shi L, et al. Effects of a New Enzymatic Debrider (SN514-066b) on Eschar Protein Digestion, Burn Wound Debridement, and Healthy Skin Irritation. Advances in Wound Care. 2025. doi:10.1089/wound.2024.0215
BibTeX
@article{Slade2025,
author = {Slade, Herbert B and Reece, Barry T and McCoy, Nick D and Roche, Eric D and Jovanovic, Aleksa V and Shi, Lei and Jacobson, Nasreen},
title = {Effects of a New Enzymatic Debrider (SN514-066b) on Eschar Protein Digestion, Burn Wound Debridement, and Healthy Skin Irritation},
journal = {Advances in Wound Care},
year = {2025},
doi = {10.1089/wound.2024.0215}
}
EUVIMED